Diabetes Obesity and Metabolism · 2025 · 10 citations · 21 references
MedicineEndocrinologyPharmacotherapyHuman NutritionObesity PreventionRenal PharmacotherapyDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlWeight LossWeight ManagementAntidiabetic Drug TherapyLipid Profile ChangesObesity TreatmentOral Antidiabetic MedicationsType 1 Diabetes PharmacotherapyWeight Loss AnalysisWeight Loss DrugWeight Loss Efficacy
AIMS: and type 1 diabetes (T1D). METHODS: This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82). Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c. RESULTS: All three agents led to significant weight loss. Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001). Dose-dependent reductions were observed for tirzepatide and semaglutide. Tirzepatide, semaglutide and liraglutide modestly reduced HbA1c by 0.65% (p = 0.004), 0.33% (p = 0.034) and 0.23% (p = 0.017), respectively. LDL-cholesterol was reduced by semaglutide (p = 0.05) and liraglutide (p = 0.02), and liraglutide also lowered the urine albumin-to-creatinine ratio (p = 0.007). There was no change in body weight and HbA1c in the usual care group. No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group. CONCLUSION: Tirzepatide, semaglutide, and liraglutide reduced bodyweight and improved in selected metabolic risk markers over 12 months without increasing the risk for hypoglycaemia or DKA. Weight loss appeared less compared with patients without diabetes. Tirzepatide, semaglutide and liraglutide modestly improved glycaemic control in adults with T1D and obesity. These findings support the potential adjunctive role of GLP-1 receptor agonists in people with obesity and T1D and underscore the need for further validation through randomized controlled trials.
21
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 4.5K citations · Full text
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022 · 3.2K citations · Full text
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text
Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.3K citations · Full text